CorMedix, Inc. (CRMD)
8.43
-0.04
(-0.47%)
USD |
NASDAQ |
Sep 04, 16:00
8.44
+0.01
(+0.12%)
After-Hours: 20:00
CorMedix Research and Development Expense (Quarterly) : 6.684M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.684M |
| March 31, 2026 | 7.212M |
| December 31, 2025 | 8.60M |
| September 30, 2025 | 5.098M |
| June 30, 2025 | 2.443M |
| March 31, 2025 | 3.192M |
| December 31, 2024 | 1.727M |
| September 30, 2024 | 0.7271M |
| June 30, 2024 | 0.651M |
| March 31, 2024 | 0.8374M |
| December 31, 2023 | 2.289M |
| September 30, 2023 | 2.664M |
| June 30, 2023 | 4.795M |
| March 31, 2023 | 3.408M |
| December 31, 2022 | 2.843M |
| September 30, 2022 | 2.339M |
| June 30, 2022 | 3.210M |
| March 31, 2022 | 2.288M |
| December 31, 2021 | 3.235M |
| September 30, 2021 | 4.741M |
| June 30, 2021 | 2.520M |
| March 31, 2021 | 2.636M |
| December 31, 2020 | 2.294M |
| September 30, 2020 | 2.925M |
| June 30, 2020 | 5.685M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.472M |
| December 31, 2019 | 2.677M |
| September 30, 2019 | 2.521M |
| June 30, 2019 | 2.980M |
| March 31, 2019 | 2.875M |
| December 31, 2018 | -4.347M |
| September 30, 2018 | 8.289M |
| June 30, 2018 | 6.600M |
| March 31, 2018 | 8.280M |
| December 31, 2017 | 8.458M |
| September 30, 2017 | 6.014M |
| June 30, 2017 | 5.090M |
| March 31, 2017 | 4.924M |
| December 31, 2016 | 4.032M |
| September 30, 2016 | 6.840M |
| June 30, 2016 | 2.773M |
| March 31, 2016 | 2.090M |
| December 31, 2015 | 1.485M |
| September 30, 2015 | 1.764M |
| June 30, 2015 | 1.798M |
| March 31, 2015 | 1.234M |
| December 31, 2014 | 0.5011M |
| September 30, 2014 | 0.2927M |
| June 30, 2014 | 0.1719M |
| March 31, 2014 | 0.353M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Innoviva, Inc. | 5.19M |
| Zevra Therapeutics, Inc. | 4.486M |
| Filana Therapeutics, Inc. | 3.303M |
| Eloxx Pharmaceuticals, Inc. | 2.84M |
| Cannabis Global, Inc. | -- |